Cost-utility analysis of camrelizumab plus chemotherapy versus chemotherapy alone as a first-line treatment for advanced nonsquamous non-small cell lung cancer in china

HIGHLIGHTS

• who: Ting Chen from the Cancer in China University Erlangen, Germany have published the research: Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China, in the Journal: (JOURNAL) of December/28,/2020
• what: In this study, cost-utility analysis was carried out by constructing and simulating a Markov model run in TreeAge Pro 2011 (TreeAge Software Inc, Williamstown, MA, USA). The output indicators of the model were the cost and quality-adjusted life years (QALYs) of the two groups . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.